A Phase 3, Open Label, Trial, Evaluating the safety, tolerability and Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Children Previously Partially Immunized with Prevenar

Registry ID

EUCTR2008-003631-21

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Wyeth Research Division of Wyeth Pharmaceuticals Inc.

Start date

2009-02-17

Completion date

2010-06-23

Last update

2026-08-16

Conditions

• Healthy infants

Summary

To assess the pneumococcal immune response induced by 13vPnC when measured 1 month after the infant dose of 13vPnC in Group 1.

Locations

• , , Sweden

View on source registry